HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

EGIS-8332

structure in first source

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - Benzodiazepines: 8452
        EGIS-8332: 4

Experts

1.	Barkóczy, József: 2 articles (12/2006 - 09/2004)
2.	Gigler, Gábor: 2 articles (12/2006 - 09/2004)
3.	Hársing, László G: 2 articles (12/2006 - 09/2004)
4.	Lévay, György: 2 articles (12/2006 - 09/2004)
5.	Matucz, Eva: 2 articles (12/2006 - 09/2004)
6.	Móricz, Krisztina: 2 articles (12/2006 - 09/2004)
7.	Szénási, Gábor: 2 articles (12/2006 - 09/2004)
8.	Agoston, M: 1 article (09/2007)
9.	Albert, M: 1 article (09/2007)
10.	Barkóczy, J: 1 article (09/2007)

Related Diseases

1.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 09/01/2007 - "EGIS-8332 dose-dependently reduced cerebral infarct size after permanent middle cerebral artery occlusion in mice and rats (minimum effective dose=3 mg kg(-1) i.p.). " 12/06/2006 - "This study evaluated the therapeutic time window of neuroprotection by EGIS-8332 and GYKI 53405 in permanent and transient middle cerebral artery occlusion (MCAO) in Sprague-Dawley rats. "
2.	Stroke (Strokes) 09/01/2007 - "EGIS-8332 seems suitable for further development for the treatment of epilepsy, ischaemia and stroke based on its efficacy in a variety of experimental disease models, and on its low side effect potential." 09/05/2005 - "We therefore wished to compare the effects of GYKI 52466, GYKI 53405, EGIS-8332 and EGIS-10608, non-competitive AMPA receptor antagonists with homophthalazine chemical structures, in standard animal stroke models with effects in a neurodegenerative model--excitoxicity in newborn mice. "
3.	Cerebral Infarction 09/01/2007 - "EGIS-8332 dose-dependently reduced cerebral infarct size after permanent middle cerebral artery occlusion in mice and rats (minimum effective dose=3 mg kg(-1) i.p.). " 09/03/2004 - "In permanent focal ischemia, EGIS-8332 decreased the volume of cerebral infarction both at 10 mg/kg i.p. "
4.	Ischemia 09/03/2004 - "In transient focal ischemia, EGIS-8332 reduced the volume of necrotic brain tissue (38.7%, p<0.01) and GYKI 53405 was similarly effective (32.6%, p<0.05). " 09/03/2004 - "In permanent focal ischemia, EGIS-8332 decreased the volume of cerebral infarction both at 10 mg/kg i.p. "
5.	Infarction (Infarctions) 12/06/2006 - "Treatment with EGIS-8332 (10 mg/kg, i.p.) 60 or 120 min after permanent MCAO, decreased infarct size by 30% and 36%, respectively, and the effect of GYKI 53405 (10 mg/kg, i.p.) was similar (30% and 33%, respectively; p<0.01 all). "

Related Drugs and Biologics

1.	talampanel
2.	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
3.	AMPA Receptors (AMPA Receptor)
4.	Dihydrotachysterol (AT 10)
5.	EGIS-10608
6.	GYKI 52466
7.	propionic acid (potassium propionate)